Irma Bagdoniene: Extreme Lipoprotein(a) Equals Secondary Prevention Risk in FH Patients
Irma Bagdoniene, Cardiologist and Lipidologist at Klinikum Lippe – University Hospital for Cardiology, Angiology, and Internal Intensive Care Medicine, posted on LinkedIn:
“This study highlights a important message: patients with extreme elevations of Lp(a) already carry a cardiovascular risk equivalent to secondary prevention — even in the primary prevention setting.
Implications for clinical practice:
- LDL-C targets of ≤70 mg/dL, ideally ≤55 mg/dL, are fully justified.
- Achieving these levels often requires combination therapy, including PCSK9 inhibitors.
- These high-risk patients deserve early, intensive lipid management—not only after their first event.
A strong reminder: FH AND extreme Lp(a) is a double-hit dyslipidemia that demands aggressive and early prevention strategies.”
Title: Extreme lipoprotein(a) is a cardiovascular risk equivalent in heterozygous familial hypercholesterolemia
Authors: Martine Paquette, MSca, Bertrand Cariou, MDb, Simon-Pierre Guay, MDa,c,d, Antonio Gallo, MDe, Liam R. Brunham, MDf, Sophie Béliard, MDg, Alexis Baass, MD
Read full article here.
Stay updated with Hemostasis Today.
-
Jun 9, 2026, 11:36Chris Boshoff: FDA Approves Our Treatment for Hemophilia A and B for 2 New Patient Populations
-
Jun 9, 2026, 10:52Vaidehi Prasanth: The Role of Viscoelastic Testing in Low- and Middle-Income Countries
-
Jun 9, 2026, 10:37Maria Bruzelius: Hemophilia and Bleeding Disorder in Clinical Practice at NordCoag 2026
-
Jun 9, 2026, 10:02Understanding Factor X Deficiency – ICHCC
-
Jun 9, 2026, 09:49Lee Severin: Why Patients Love Platelet-Rich Plasma
-
Jun 9, 2026, 09:42Lorena Gerlach: Blood Transportation Duty on this Muggy Spring Day
-
Jun 9, 2026, 08:54Shujha Abbas: Understanding the Real Cost of Gene Therapie
-
Jun 9, 2026, 04:47Akshat Jain: Marstacimab Gets FDA Expension for Children with Hemophilia B
-
Jun 9, 2026, 03:30Fayad Al-Haimus: High-Risk Emergencies and Lifelong Learning at CAEP 2026